Using FET PET to Distinguish Tumor Progression from Pseudoprogression in High-Grade Glioma
Official title: 18F-FET (O-(2-[18F]Fluoroethyl)-L-tyrosine) PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Gliomas
Run by Singapore General Hospital · NCT06172595 · Data updated 2026-11-12
This study is testing if a special brain scan can help tell the difference between real tumor growth and false alarms in patients with high-grade gliomas after radiation therapy.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 22 (estimated) |
| Sponsor | Singapore General Hospital Academic / other |
| Drugs / interventions | bevacizumab |
| Locations | 2 sites (Singapore and 1 other locations) |
| Status | Recruiting |
| Started | December 21, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | February 28, 2026 |
| Registry record updated | December 3, 2024 |
| Trial ID | NCT06172595 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 21 and older with histologically confirmed malignant glioma who have undergone prior radiation therapy and exhibit enlarging lesions on MRI.
✕Probably not a fit
Patients with low-grade gliomas, IDH-mutated gliomas, or those who have received anti-angiogenic treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging in differentiating between true tumor progression and pseudoprogression in patients with high-grade gliomas. Participants will undergo a limited FET PET/CT scan of the brain to assess the diagnostic accuracy of this imaging technique. The study aims to optimize threshold cut-offs for various parameters to improve the sensitivity and specificity of FET PET in identifying disease progression. The trial focuses on patients with equivocal conventional imaging results following radiation therapy.
Why it matters
Potential benefit: If successful, this study could provide a more accurate diagnostic tool for distinguishing between tumor progression and pseudoprogression, leading to better treatment decisions for patients with high-grade gliomas.
How similar studies have gone: Other studies have shown promising results using advanced PET imaging techniques for similar diagnostic challenges, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or Women, aged 21 years or older at time of screening * Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour * With enlarging contrast-enhancing and/or T2W/FLAIR-hyperintense lesion(s) on MRI within the previous RT field * Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry * Subject must consent to undergo all study procedures Exclusion Criteria: * Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17 * Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments. * Proven cerebral metastases * IDH-mutated gliomas * Pregnancy/ breast-feeding
Where it's running
-
National Cancer Centre Singapore
Singapore, Singapore Recruiting -
Singapore General Hospital
Singapore, Singapore Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma
This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.
-
C5252 injection for intracranial glioma
A phase I/IIa study tests C5252 given into the brain to see if it is safe and whether it helps people with recurrent malignant glioma after standard therapies.
-
Using 18F-TRX to image solid tumors
This trial tests whether the 18F-TRX PET tracer can detect tumors in adults with advanced solid tumors such as high‑grade glioma, clear cell renal cell carcinoma, or metastatic castration‑resistant prostate cancer.
-
Testing TNG456 and Abemaciclib in Patients with Solid Tumors Lacking MTAP
This study is testing a new drug called TNG456, alone and with another drug called abemaciclib, to see if it helps people with advanced solid tumors that have lost a specific gene called MTAP.
-
Testing DSP-0390 in patients with IDH-mutant gliomas
This study is testing a new drug called DSP-0390 in patients with specific types of brain tumors to see if it helps kill more tumor cells during surgery.
-
Cognitive rehabilitation program for patients with diffuse glioma
This study is testing a new online brain training program to see if it can help people with diffuse glioma improve their memory and thinking skills after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.